摘要:
sci-hub.se 参考文章(20)
Alan D. Lopez, Christopher J. L. Murray, The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. Harvard School of Public Health on behalf of the World Health Organization and the World Bank , Distributed by Harvard University Press. ,(1996)
L. A. Leiter, P. Lundman, P. M. da Silva, H. Drexel, C. Jünger, A. K. Gitt, , Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study Diabetic Medicine. ,vol. 28, pp. 1343- 1351 ,(2011) , 10.1111/J.1464-5491.2011.03360.X
P. Ferre, The Biology of Peroxisome Proliferator-Activated Receptors: Relationship With Lipid Metabolism and Insulin Sensitivity Diabetes. ,vol. 53, ,(2004) , 10.2337/DIABETES.53.2007.S43
, Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano, , , ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)☆☆☆ Atherosclerosis. ,vol. 32, pp. 1769- 1818 ,(2011) , 10.1093/EURHEARTJ/EHR158
Rajendra H. Jani, Kevinkumar Kansagra, Mukul R. Jain, Harilal Patel, Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects Clinical Drug Investigation. ,vol. 33, pp. 809- 816 ,(2013) , 10.1007/S40261-013-0128-3
Rajendrakumar H. Jani, Vikas Pai, Pramod Jha, Gunjan Jariwala, Satinath Mukhopadhyay, Anil Bhansali, Shashank Joshi, A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI) Diabetes Technology & Therapeutics. ,vol. 16, pp. 63- 71 ,(2014) , 10.1089/DIA.2013.0253
Shashank R Joshi, Ranjit Mohan Anjana, Mohan Deepa, Rajendra Pradeepa, Anil Bhansali, Vinay K Dhandania, Prashant P Joshi, Ranjit Unnikrishnan, Elangovan Nirmal, Radhakrishnan Subashini, Sri Venkata Madhu, Paturi Vishnupriya Rao, Ashok Kumar Das, Tanvir Kaur, Deepak Kumar Shukla, Viswanathan Mohan, ICMR–INDIAB Collaborative Study Group, None, Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study PLoS ONE. ,vol. 9, pp. e96808- ,(2014) , 10.1371/JOURNAL.PONE.0096808
Rakesh M. Parikh, Shashank R. Joshi, Padmavathy S. Menon, Nalini S. Shah, Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients Diabetes & Metabolic Syndrome: Clinical Research & Reviews. ,vol. 4, pp. 10- 12 ,(2010) , 10.1016/J.DSX.2009.04.005
Andrea Cignarella, Stefano Bellosta, Alberto Corsini, Chiara Bolego, Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research. ,vol. 53, pp. 492- 500 ,(2006) , 10.1016/J.PHRS.2006.03.012
Brad R. Henke, Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes Journal of Medicinal Chemistry. ,vol. 47, pp. 4118- 4127 ,(2004) , 10.1021/JM030631E